Premier Research's regulatory strategists specializing in the US FDA’s 505(b)(2) approval pathway are often asked how a sponsor can recover from a pre-IND meeting that doesn’t go as planned. While we firmly believe that setbacks can be turned into opportunities...
Expertise: Consulting 225 results
Consulting
Strategic Considerations for Bridging
Consulting
Strategic Considerations for Bridging
Consulting
Greg Meyer, RAC, CQA
Consulting
Olu Aloba, Ph.D.
Clinical Development